Comment on "Safety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic Risk".

作者信息

Moura Carlos Antonio, Rosa Fabiana Santos, Assis Luiz Henrique, Moura Carlos Geraldo

机构信息

Hospital Santo Antonio, Obras Sociais Irmã Dulce, Salvador, Brazil.

Universidade Salvador (UNIFACS), Salvador, Brazil.

出版信息

Drugs Aging. 2021 Jun;38(6):535-537. doi: 10.1007/s40266-021-00857-3. Epub 2021 Apr 19.

DOI:10.1007/s40266-021-00857-3

PMID:33871804

Abstract

摘要

相似文献

Comment on "Safety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic Risk".

Drugs Aging. 2021 Jun;38(6):535-537. doi: 10.1007/s40266-021-00857-3. Epub 2021 Apr 19.

Authors' Reply to Moura et al.: "Safety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic Risk".

Drugs Aging. 2021 Jun;38(6):539-541. doi: 10.1007/s40266-021-00856-4. Epub 2021 Apr 19.

Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?

Drug Saf. 2018 Jul;41(7):645-653. doi: 10.1007/s40264-018-0651-5.

Thromboembolic Safety Reporting of Tofacitinib and Baricitinib: An Analysis of the WHO VigiBase.

Drug Saf. 2020 Sep;43(9):881-891. doi: 10.1007/s40264-020-00958-9.

Thromboembolism and Janus Kinase Inhibitors.

Drug Saf. 2020 Sep;43(9):831-833. doi: 10.1007/s40264-020-00973-w.

Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors.

Drug Saf. 2018 Apr;41(4):357-361. doi: 10.1007/s40264-017-0622-2.

Pharmacology and safety of tofacitinib in ulcerative colitis.

Gastroenterol Hepatol. 2021 Jan;44(1):39-48. doi: 10.1016/j.gastrohep.2020.04.012. Epub 2020 Aug 20.

Thromboembolic events in Janus kinase inhibitors: A pharmacovigilance study from 2012 to 2021 based on the Food and Drug Administration's Adverse Event Reporting System.

Br J Clin Pharmacol. 2022 Sep;88(9):4180-4190. doi: 10.1111/bcp.15361. Epub 2022 May 2.

Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.

Ann Rheum Dis. 2020 Nov;79(11):1400-1413. doi: 10.1136/annrheumdis-2019-216761. Epub 2020 Aug 5.

Long-term safety data for tofacitinib, an oral Janus kinase inhibitor, for the treatment for psoriasis.

Br J Dermatol. 2018 Oct;179(4):815-816. doi: 10.1111/bjd.17016.

引用本文的文献

Authors' Reply to Moura et al.: "Safety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic Risk".

Drugs Aging. 2021 Jun;38(6):539-541. doi: 10.1007/s40266-021-00856-4. Epub 2021 Apr 19.

本文引用的文献

Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2.

Ann Rheum Dis. 2021 Mar;80(3):312-320. doi: 10.1136/annrheumdis-2020-218870. Epub 2020 Dec 3.

Safety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic Risk.

Drugs Aging. 2020 Aug;37(8):551-558. doi: 10.1007/s40266-020-00775-w.

Cardiovascular Toxicity in Cancer Patients Treated with Tyrosine Kinase Inhibitors: A Real-World Single-Center Experience.

Oncology. 2020;98(7):445-451. doi: 10.1159/000505486. Epub 2020 Apr 29.

Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis.

Blood Adv. 2020 Jan 28;4(2):380-386. doi: 10.1182/bloodadvances.2019001158.

Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations.

Arthritis Res Ther. 2019 Aug 2;21(1):183. doi: 10.1186/s13075-019-1964-1.

Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?

Drug Saf. 2018 Jul;41(7):645-653. doi: 10.1007/s40264-018-0651-5.

Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors.

Drug Saf. 2018 Apr;41(4):357-361. doi: 10.1007/s40264-017-0622-2.

The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review).

Int J Mol Med. 2017 Aug;40(2):271-280. doi: 10.3892/ijmm.2017.3036. Epub 2017 Jun 22.

The effects of JAK inhibitor therapy upon novel markers of thrombosis In myeloproliferative neoplasms.

Haematologica. 2015 Sep;100(9):e348-50. doi: 10.3324/haematol.2015.128918. Epub 2015 Jun 18.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验